Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Apotex Inc. v. Daiichi Sankyo, Inc. et al
Case Number:
1:12-cv-09295
Court:
Nature of Suit:
Judge:
Honorable Sharon Johnson Coleman
Firms
Companies
Sectors & Industries:
-
January 11, 2016
Apotex Doesn't Infringe Patent For Benicar, Judge Says
A federal judge ruled Friday that Apotex's planned generic version of Daiichi Sankyo's blood pressure drug Benicar does not infringe a patent that Daiichi previously disclaimed, a decision that could reduce the generic exclusivity period held by Apotex's rival generics maker Mylan.
-
April 10, 2013
Mylan Blasts Apotex Challenge To Generic Benicar Exclusivity
Mylan Pharmaceuticals Inc. Tuesday blasted Apotex Inc.'s attempt to strip it of its exclusive rights to market a generic version of Daiichi Sankyo Co. Ltd.'s hypertension drug Benicar, urging an Illinois federal judge to toss the case because Apotex's quest is impossible.
-
November 20, 2012
Apotex Targets Exclusivity Period In Generic Benicar Suit
Apotex Inc. slapped Daiichi Sankyo Co. Ltd. with a patent suit in Illinois on Tuesday, seeking a noninfringement ruling which Apotex said could strip Mylan Laboratories Ltd. of exclusive rights to market a generic version of the hypertension drug Benicar.